NBP
Income statement / Annual
Last year (2025), NovaBridge Biosciences.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, NovaBridge Biosciences.'s net income was -$6.61 M.
See NovaBridge Biosciences.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$4.49 M |
-$10.70 M |
$88.03 M |
$1.54 B |
$30.00 M |
$53.78 M |
$11.27 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$46.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$4.49 M
|
-$10.70 M
|
$41.59 M
|
$1.54 B
|
$30.00 M
|
$53.78 M
|
$11.56 M
|
| Gross Profit Ratio |
0
|
0
|
1
|
1
|
0.47
|
1
|
1
|
1
|
1.03
|
| Research and Development Expenses |
$8.99 M
|
$158.90 M
|
$114.36 M
|
$155.51 M
|
$190.29 M
|
$984.69 M
|
$840.42 M
|
$426.03 M
|
$267.08 M
|
| General & Administrative Expenses |
$4.48 M
|
$216.46 M
|
$63.91 M
|
$199.88 M
|
$899.94 M
|
$402.41 M
|
$654.55 M
|
$66.39 M
|
$25.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.48 M
|
$216.46 M
|
$63.91 M
|
$199.88 M
|
$899.94 M
|
$402.41 M
|
$654.55 M
|
$66.39 M
|
$25.44 M
|
| Other Expenses |
$0.00
|
$0.00
|
$337.38 M
|
-$247.00
|
$1.02 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$13.48 M
|
$375.36 M
|
$515.65 M
|
$355.38 M
|
$2.11 B
|
$1.39 B
|
$1.49 B
|
$492.42 M
|
$292.51 M
|
| Cost And Expenses |
$13.48 M
|
$375.36 M
|
$515.65 M
|
$355.38 M
|
$2.16 B
|
$1.39 B
|
$1.49 B
|
$492.42 M
|
$285.15 M
|
| Interest Income |
$1.09 M
|
$54.64 M
|
$7.30 M
|
$4.95 M
|
$21.33 M
|
$3.71 M
|
$4.37 M
|
$668.27 K
|
$131.42 K
|
| Interest Expense |
$0.00
|
$0.00
|
$101.85 K
|
$0.00
|
$0.00
|
$146.48 K
|
$427.48 K
|
$1.70 M
|
$864.34 K
|
| Depreciation & Amortization |
$122.37 K
|
$1.91 M
|
$3.37 M
|
$1.42 M
|
$13.78 M
|
$12.74 M
|
$9.83 M
|
$6.74 M
|
$1.63 M
|
| EBITDA |
-$13.35 M |
-$373.45 M |
-$344.25 M |
-$51.23 M |
-$2.06 B |
$168.31 M |
-$197.26 M |
-$431.90 M |
-$279.32 M |
| EBITDA Ratio |
0
|
0
|
-76.74
|
4.79
|
-23.37
|
0.11
|
-6.58
|
-8.03
|
-24.79
|
| Operating Income Ratio |
0
|
0
|
-113.95
|
34.22
|
-23.53
|
0.1
|
-48.83
|
-8.47
|
-24.31
|
| Total Other Income/Expenses Net |
$847.61 K
|
$12.63 M
|
-$954.53 M
|
-$607.09 M
|
-$260.73 M
|
$327.58 M
|
$13.02 M
|
$38.99 M
|
-$16.85 M
|
| Income Before Tax |
-$12.63 M
|
-$362.73 M
|
-$1.47 B
|
-$973.17 M
|
-$2.33 B
|
$483.15 M
|
-$1.45 B
|
-$416.76 M
|
-$290.74 M
|
| Income Before Tax Ratio |
0
|
0
|
-326.74
|
90.97
|
-26.49
|
0.31
|
-48.4
|
-7.75
|
-25.81
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.26 B
|
$710.39 K
|
-$494.81 K
|
$12.23 M
|
$0.00
|
$1.72 M
|
$0.00
|
| Net Income |
-$6.61 M
|
-$162.26 M
|
-$1.47 B
|
-$2.51 B
|
-$2.33 B
|
$470.92 M
|
-$1.45 B
|
-$402.83 M
|
-$298.24 M
|
| Net Income Ratio |
0
|
0
|
-326.74
|
234.39
|
-26.49
|
0.31
|
-48.27
|
-7.49
|
-26.47
|
| EPS |
-0.16 |
-4.46 |
-17.62 |
-30.38 |
-30.7 |
8.07 |
-25.53 |
-6.92 |
-5.13 |
| EPS Diluted |
-0.16 |
-4.46 |
-17.62 |
-30.38 |
-30.68 |
6.9 |
-25.53 |
-6.92 |
-5.13 |
| Weighted Average Shares Out |
$41.64 M
|
$81.19 M
|
$83.19 M
|
$82.52 M
|
$75.93 M
|
$68.25 M
|
$58.17 M
|
$58.17 M
|
$58.17 M
|
| Weighted Average Shares Out Diluted |
$41.64 M
|
$81.19 M
|
$83.23 M
|
$82.52 M
|
$75.96 M
|
$68.36 M
|
$58.17 M
|
$58.17 M
|
$58.17 M
|
| Link |
|
|
|
|
|
|
|
|
|
